First efficacy and safety study of femtosecond lenticule extraction for the correction of myopia: Six-month results
Accepted 29 May 2008.
Refers to erratum:
Erratum
Journal of Cataract & Refractive Surgery
November 2008 (Vol. 34, Issue 11, Page 1819) Full Text |
Full-Text PDF (55 KB)
Purpose
To prospectively study the feasibility of femtosecond lenticule extraction (FLE), a new method of refractive correction.
Setting
Department of Ophthalmology, Philipps University of Marburg and Helios Clinic, Erfurt, Germany.
Methods
A flap and a lenticule of intrastromal corneal tissue were simultaneously cut with a VisuMax femtosecond laser system. Next, the lenticule was manually removed and the flap repositioned. The target refraction in all cases was −0.75 diopter (D).
Results
All 10 myopic eyes in the initial treatment group completed the final 6-month follow-up. The mean patient age was 39 years. The mean spherical equivalent (SE) was −4.73 ± 1.48 (SD) preoperatively and −0.33 ± 0.61 D 6 months postoperatively. Ninety percent of eyes were within ±1.00 D and 40% were within ±0.50 D of the intended correction. No eye lost 2 or more Snellen lines. Corneal topography showed large, prolate optical zones. Aberrometry showed no significant induction of higher-order aberrations. On a standardized questionnaire, all patients said they were very satisfied with the results.
Conclusions
Preliminary results indicate that FLE is a promising new corneal refractive procedure to correct myopia.
From the Departments of Ophthalmology, Gutenberg University, Mainz and Philipps University, Marburg (Sekundo), and Helios Clinic Erfurt (Kunert, Blum), Erfurt, and Carl Zeiss Meditec AG (Russmann, Gille, Bissmann, Stobrawa, Sticker, Bischoff), Jena, Germany
Corresponding author: Prof. Dr. med. Walter Sekundo, Universitäts-Augenklinik, Langenbeckstrasse 1, 55131 Mainz, Germany.
Drs. Russmann, Gille, Bissmann, Stobrawa, Sticker, and Bischoff are employees of Carl Zeiss Meditec AG. No other author has a financial or proprietary interest in any material or method mentioned.
Supported by Carl Zeiss Meditec AG.
Michael Schroeder, MD, University Eye Hospital of Marburg, Germany, examined several patients in the study.
ABSTRACT